A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Public ClinicalTrials.gov record NCT05091346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
Study identification
- NCT ID
- NCT05091346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Interventions
- E7386 Drug
- Lenvatinib Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2021
- Primary completion
- Oct 14, 2024
- Completion
- Oct 14, 2024
- Last update posted
- Oct 23, 2025
2021 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of California, Irvine Health | Orange | California | 92868 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| SCRI Florida Cancer Specialists East | West Palm Beach | Florida | 33401 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Rutgers cancer Institute of NJ | New Brunswick | New Jersey | 08901 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Providence Medical Center Institute Franz Clinic | Portland | Oregon | 97213 | — |
| Tennessee Oncology PPLC | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05091346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05091346 live on ClinicalTrials.gov.